Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 345 across all filing types
Latest filing 2025-05-13 Earnings Release
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 100% confidence The document is titled "MaaT Pharma fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2025" (MaaT Pharma provides an update on its activities and publishes its financial results for the first quarter of 2025). It explicitly reports key financial figures for Q1 2025 (Revenue of €1.1 million, Cash position as of March 31, 2025) alongside significant clinical and operational updates. This structure—a concise announcement of period-specific financial results (Q1) with key operational highlights—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (like an Annual Report 10-K or an Interim Report IR), nor is it merely an announcement of a report's publication (RPA). The document is dated May 13, 2025, reporting on the period ending March 31, 2025, which aligns with the typical timing for a Q1 earnings announcement. Q1 2025
2025-05-13 French
Inside Information / Other news releases
Earnings Release Classification · 100% confidence The document is titled "MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025". It contains key financial highlights (Revenues of €1.1 million, Cash position as of March 31, 2025), significant business updates (Phase 3 trial results, DSMB reviews), and an outlook. This structure is characteristic of an Earnings Release (ER), which provides initial announcements of periodical financial results and key operational highlights, rather than the comprehensive, audited report (10-K) or the detailed management discussion (MDA). It is not a transcript (CT), a formal annual report (10-K), or a standalone audit report (AR). The document explicitly reports the Q1 2025 results. Q1 2025
2025-05-13 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated May 12, 2025, announcing 'données finales prometteuses' (promising final data) from a Phase 1b clinical trial (IASO) evaluating MaaT033 for Amyotrophic Lateral Sclerosis (ALS). It details safety, tolerability, microbiome implantation, and preliminary efficacy signals (slower disease progression based on ALSFRS-R scores). This content—the initial announcement of key periodic financial/clinical results, often including management commentary and forward-looking statements—is characteristic of an Earnings Release (ER) or a specific clinical data release. Since the document focuses entirely on the release of new clinical trial results and associated management commentary, it fits best under the 'Earnings Release' category, which serves as the primary vehicle for announcing periodic performance highlights, even if the performance metric here is clinical trial data rather than quarterly revenue. It is not a full Annual Report (10-K), a transcript (CT), or a formal Audit Report (AR). Given the context of a biotech company releasing trial data, ER is the most appropriate fit among the provided options for a primary results announcement. Q1 2025
2025-05-12 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated May 12, 2025, announcing 'Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)'. It details clinical trial results, safety profiles, and future development plans, including seeking partners. This content structure—announcing key results and providing context about the drug and company—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical updates. Since it is focused on announcing clinical data and business strategy updates rather than being a formal, comprehensive financial report (like a 10-K or IR), 'ER' (Earnings Release) is the closest fit for a major operational announcement, although 'RNS' (Regulatory Filings) is also plausible for non-standard announcements. Given the focus on announcing key data points and business outlook, ER is selected as the primary category for a significant operational update, even if it's not strictly quarterly earnings. Q2 2025
2025-05-12 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 28, 2025, announcing that MaaT Pharma is presenting new preclinical data for its drug candidate MaaT034 at the American Association for Cancer Research (AACR) annual conference. It details scientific results, discusses ongoing clinical trials (Phase 2 and 3 for other candidates), and lists upcoming investor conferences. This format—a formal announcement of scientific findings and corporate updates outside of mandatory periodic financial filings (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release detailing operational/scientific progress. Since it focuses on presenting new scientific data and operational milestones rather than just summarizing quarterly financial performance (which would be ER), and it is not a transcript (CT), investor presentation (IP), or a formal regulatory filing like 10-K, the most appropriate classification for a press release detailing scientific progress and upcoming events is Earnings Release (ER), as these often overlap with scientific updates in biotech, or Regulatory Filing (RNS) as a general announcement. Given the focus on presenting specific scientific data (preclinical results) and listing future conference participation, it functions as a key corporate update. In the context of biotech, announcements of data presentations are often categorized under ER if they are timely updates, or RNS if they are general news. Since it is a formal announcement of results and corporate activity, ER is a strong fit, but RNS is the safest fallback for non-standard announcements. However, since it is a detailed announcement of scientific progress and corporate news, and not just a link to a report, ER (Earnings Release, often used broadly for key periodic updates) or RNS (Regulatory Filings/General Announcement) are candidates. Given the content is primarily scientific data presentation and corporate news, and not a formal financial report, RNS is the most accurate general category for this type of press release that doesn't fit the specific financial report codes.
2025-04-28 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is a press release dated April 28, 2025, announcing that MaaT Pharma presented preclinical data for its product MaaT034 at the AACR Annual Meeting. It details scientific results, includes quotes from the CMO, lists upcoming conference participation, and contains standard 'About' and 'Forward-looking Statements' sections, concluding with contact information. This format is characteristic of an initial announcement of scientific or operational news, rather than a comprehensive regulatory filing (like 10-K or IR) or a transcript. Since it is an announcement of results presented at a scientific meeting, it most closely aligns with an Earnings Release (ER) if it were financial results, but since it is scientific/clinical data presentation, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially an Investor Presentation (IP) if it were the slides themselves. Given the structure as a press release detailing new data, RNS is the most appropriate general category for non-standard, non-financial corporate news releases, although it shares characteristics with an IP. However, it is not a formal presentation document, but a news release *about* the presentation. Therefore, RNS (Regulatory Filings/General Announcement) is the best fit among the provided options for a scientific press release. FY 2025
2025-04-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.